Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve.


Journal

NEJM evidence
ISSN: 2766-5526
Titre abrégé: NEJM Evid
Pays: United States
ID NLM: 9918317485806676

Informations de publication

Date de publication:
Jul 2023
Historique:
medline: 6 2 2024
pubmed: 6 2 2024
entrez: 6 2 2024
Statut: ppublish

Résumé

Apixaban, Warfarin, and On-X Mechanical Aortic ValvesAlthough vitamin K antagonists are the only oral anticoagulants approved with mechanical heart valves, this trial examined whether apixaban could be safely used in patients with an On-X mechanical aortic valve. A total of 863 such patients were assigned apixaban 5 mg twice daily or warfarin (target international normalized ratio 2.0 to 3.0). A total of 20 thrombotic events occurred in the apixaban group (4.2%/patient-year) and 6 events in the warfarin group (1.3%/patient-year). Major bleeding rates were 3.6%/patient-year with apixaban and 4.5%/patient-year with warfarin.

Identifiants

pubmed: 38320162
doi: 10.1056/EVIDoa2300067
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

EVIDoa2300067

Auteurs

Tracy Y Wang (TY)

Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.

Lars G Svensson (LG)

Cleveland Clinic, Cleveland.

Jun Wen (J)

Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.

Andrew Vekstein (A)

Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.

Marc Gerdisch (M)

Franciscian Health, Indianapolis.

Vijay U Rao (VU)

Franciscian Health, Indianapolis.

Michael Moront (M)

ProMedica Toledo Hospital, Toledo, OH.

Doug Johnston (D)

Cleveland Clinic, Cleveland.

Renato D Lopes (RD)

Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.

Alma Chavez (A)

Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.

Marc Ruel (M)

University of Ottawa Heart Institute, Ottawa, ON.

Eugene H Blackstone (EH)

Cleveland Clinic, Cleveland.

Richard C Becker (RC)

University of Cincinnati College of Medicine, Cincinnati.

Vinod Thourani (V)

Piedmont Heart Institute, Atlanta.

John Puskas (J)

Mount Sinai Morningside Hospital, New York.

Hussein R Al-Khalidi (HR)

Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.

David G Cable (DG)

OSF HealthCare Cardiovascular Institute, Rockford, IL.

John A Elefteriades (JA)

Yale University School of Medicine, New Haven, CT.

Alberto Pochettino (A)

Mayo Clinic, Rochester, MN.

J Alan Wolfe (JA)

Northeast Georgia Medical Center, Gainesville, GA.

Allen Graeve (A)

MultiCare Institute for Research and Innovation, Tacoma, WA.

Ibrahim Sultan (I)

University of Pittsburgh Medical Center, Pittsburgh.

Ashraf A Sabe (AA)

Brigham and Women's Hospital, Harvard Medical School, Boston.

Hector I Michelena (HI)

Mayo Clinic, Rochester, MN.

John H Alexander (JH)

Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.

Classifications MeSH